The Deloitte 2021 North America Technology Fast 500 includes seven North Carolina companies, with Nufabrx ranking 8th. Pendo, Sift Media, FM:Systems, vTV Therapeutics, Precision BioSciences, and MedShift also appear ranked.
Read More
Precision BioSciences, a clinical stage biotechnology company focusing on genome editing therapies, on Monday announced Michael Amoroso as its new chief executive officer.
Read More
Durham-based Precision Biosciences inked a new partnership deal this week.
Read More
Earnings season continues with seven Triangle firms updating their financial reports this week. Here they are.
Read More
A new research study contains promising results for Precision Biosciences proprietary gene-editing technology.
Read More
Precision Biosciences, Fathom Holdings and Tenax Therapeutics recently reported quarterly earnings. Here’s a recap.
Read More
The Durham clinical-stage biotechnology company has received U.S. Food and Drug Administration approval to advance its new drug for patients with relapsed/refractory non-Hodgkin Lymphoma.
Read More
Global pharmaceutical giant Eli Lilly and Company is interested in Durham-based Precision Biosciences’ genome editing technology and it’s putting its money where its interest is. Here’s a look at the mega deal between the two firms.
Read More
Lilly and Durham-based Precision BioSciences disclose a deal involving Precision’s gene editing technology on Friday morning that could be worth as much as $555 million. Duchenne muscular dystrophy is the initial target.
Read More
